Protalix BioTherapeutics Assures Uninterrupted Operations Amid Security Situation in Israel
Protalix BioTherapeutics, a leading biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins, has released a statement regarding the current security situation in Israel. Despite the ongoing events, Protalix reassures its employees, partners, and stockholders that its operations remain unaffected.
Dror Bashan, President and CEO of Protalix, expressed the company’s deep sorrow and sympathy for the victims and their families affected by the recent events. He emphasized that Protalix is dedicated to supporting its own employees, friends, and colleagues during this difficult time.
Fortunately, Protalix’s facilities have not been impacted by the hostilities, and the supply of their key products, Elfabrio® and Elelyso®, is expected to continue without disruption. The company extends its gratitude to partners and stockholders who have shown support and confidence in Protalix during this challenging period.
Protalix’s ProCellEx® plant cell-based protein expression system is a groundbreaking technology that enables the development of recombinant therapeutic proteins in an industrial-scale manner. The company has gained FDA approval for taliglucerase alfa, a protein produced through this system, for the treatment of Gaucher disease. Protalix has also received regulatory approvals for Elfabrio®, its second product, and has partnered with Chiesi Farmaceutici S.p.A. for its global development and commercialization.
In addition to its existing products, Protalix has a robust pipeline of proprietary versions of recombinant therapeutic proteins targeting various pharmaceutical markets. These include PRX-115, a plant cell-expressed recombinant PEGylated uricase for severe gout, and PRX-119, a plant cell-expressed long-action DNase I for NETs-related diseases.
Protalix remains committed to advancing its innovative therapies and contributing to the healthcare industry. The company’s dedication to maintaining uninterrupted operations during this challenging time is a testament to its resilience and commitment to patients worldwide.